vs
STANDARD BIOTOOLS INC.（LAB）与Zevia PBC（ZVIA）财务数据对比。点击上方公司名可切换其他公司
Zevia PBC的季度营收约是STANDARD BIOTOOLS INC.的1.9倍（$37.9M vs $19.6M），Zevia PBC净利率更高（-3.4% vs -177.4%，领先174.0%），Zevia PBC同比增速更快（-4.0% vs -11.5%），过去两年Zevia PBC的营收复合增速更高（-1.2% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
泽维亚PBC是一家总部位于美国洛杉矶的饮品企业，主打用甜菊糖调味的汽水、有机茶、能量饮料及调酒精饮，全系列产品均为零卡无糖，同时符合无麸质、纯素、犹太洁食认证以及非转基因项目认证，2021年6月该公司递交申请启动首次公开募股。
LAB vs ZVIA — 直观对比
营收规模更大
ZVIA
是对方的1.9倍
$19.6M
营收增速更快
ZVIA
高出7.4%
-11.5%
净利率更高
ZVIA
高出174.0%
-177.4%
两年增速更快
ZVIA
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $37.9M |
| 净利润 | $-34.7M | $-1.3M |
| 毛利率 | 48.5% | 47.7% |
| 营业利润率 | -168.5% | -4.0% |
| 净利率 | -177.4% | -3.4% |
| 营收同比 | -11.5% | -4.0% |
| 净利润同比 | -28.8% | 80.9% |
| 每股收益（稀释后） | $-0.09 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABZVIA
| Q4 25 | — | $37.9M | ||
| Q3 25 | $19.6M | $40.8M | ||
| Q2 25 | $21.8M | $44.5M | ||
| Q1 25 | $40.8M | $38.0M | ||
| Q4 24 | — | $39.5M | ||
| Q3 24 | $22.1M | $36.4M | ||
| Q2 24 | $22.5M | $40.4M | ||
| Q1 24 | $45.5M | $38.8M |
净利润LABZVIA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-34.7M | $-2.7M | ||
| Q2 25 | $-33.5M | $-651.0K | ||
| Q1 25 | $-26.0M | $-6.4M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | $-26.9M | $-2.5M | ||
| Q2 24 | $-45.7M | $-7.0M | ||
| Q1 24 | $-32.2M | $-7.2M |
毛利率LABZVIA
| Q4 25 | — | 47.7% | ||
| Q3 25 | 48.5% | 45.6% | ||
| Q2 25 | 48.8% | 48.7% | ||
| Q1 25 | 48.4% | 50.1% | ||
| Q4 24 | — | 49.2% | ||
| Q3 24 | 54.9% | 49.1% | ||
| Q2 24 | 46.1% | 41.9% | ||
| Q1 24 | 53.1% | 45.7% |
营业利润率LABZVIA
| Q4 25 | — | -4.0% | ||
| Q3 25 | -168.5% | -7.0% | ||
| Q2 25 | -118.1% | -2.3% | ||
| Q1 25 | -80.8% | -16.8% | ||
| Q4 24 | — | -16.1% | ||
| Q3 24 | -120.9% | -8.2% | ||
| Q2 24 | -134.5% | -17.5% | ||
| Q1 24 | -132.2% | -18.8% |
净利率LABZVIA
| Q4 25 | — | -3.4% | ||
| Q3 25 | -177.4% | -6.6% | ||
| Q2 25 | -153.7% | -1.5% | ||
| Q1 25 | -63.8% | -16.8% | ||
| Q4 24 | — | -17.2% | ||
| Q3 24 | -122.0% | -6.9% | ||
| Q2 24 | -203.3% | -17.2% | ||
| Q1 24 | -70.6% | -18.6% |
每股收益（稀释后）LABZVIA
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $-0.09 | $-0.04 | ||
| Q2 25 | $-0.09 | $-0.01 | ||
| Q1 25 | $-0.07 | $-0.08 | ||
| Q4 24 | — | $-0.10 | ||
| Q3 24 | $-0.07 | $-0.04 | ||
| Q2 24 | $-0.12 | $-0.10 | ||
| Q1 24 | $-0.27 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $25.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $51.0M |
| 总资产 | $539.6M | $63.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABZVIA
| Q4 25 | — | $25.4M | ||
| Q3 25 | $129.4M | $26.0M | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABZVIA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABZVIA
| Q4 25 | — | $51.0M | ||
| Q3 25 | $399.7M | $51.3M | ||
| Q2 25 | $424.5M | $53.0M | ||
| Q1 25 | $454.6M | $53.7M | ||
| Q4 24 | — | $64.9M | ||
| Q3 24 | $489.3M | $72.5M | ||
| Q2 24 | $510.3M | $75.0M | ||
| Q1 24 | $577.3M | $80.3M |
总资产LABZVIA
| Q4 25 | — | $63.6M | ||
| Q3 25 | $539.6M | $60.0M | ||
| Q2 25 | $557.0M | $62.5M | ||
| Q1 25 | $579.6M | $62.0M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | $681.5M | $72.9M | ||
| Q2 24 | $708.7M | $72.8M | ||
| Q1 24 | $777.7M | $85.1M |
负债/权益比LABZVIA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-507.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABZVIA
| Q4 25 | — | $-507.0K | ||
| Q3 25 | $-22.2M | $116.0K | ||
| Q2 25 | $-20.7M | $-1.4M | ||
| Q1 25 | $-30.3M | $-2.9M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | $-27.9M | $3.9M | ||
| Q2 24 | $-39.0M | $282.0K | ||
| Q1 24 | $-62.5M | $-3.2M |
自由现金流LABZVIA
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABZVIA
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABZVIA
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
ZVIA
暂无分部数据
